【摘要】 脂肪细胞型脂肪酸结合蛋白(adipocyte fatty-acid binding protein A-FABP,FABP4,或ap2),属于运输长链脂肪酸的低分子量胞浆蛋白家族成员.近年来研究发现ap2的表达量与动脉粥样硬化的发生和发展有十分密切的关系,ap2为靶点的治疗方法成为治疗动脉粥样硬化等相关疾病的焦点.为此采用ERK1/2抑制剂PD98059和UO126处理小鼠单核巨噬细胞RAW264.7和腹膜巨噬细胞,ap2的表达被明显的抑制,并呈现一定的时间和浓度依赖性.因而ERK1/2抑制剂可能对动脉粥样硬化有一定的治疗作用.更多还原

【Abstract】 The adipocyte fatty-acid binding protein(A-FABP,FABP4 or ap2)is a group of low molecular weight cytoplasmic protein super-family which can transport long-chain fatty acids.Research in recent years shows that the expression of ap2 plays an important role in the occurance and development of atherosclerosis.The treatment of ap2 as a target may be a potential therapy for atherosclerosis and related diseases.RAW264.7 cells and peritoneal macrophages by ERK1/2 inhibitors(PD98059 and UO126) were treated.The expression of ap2 was significantly inhibited compared to controls,and it reduced in a time and concentration-dependent manner.The results imply that ERK1/2 inhibitors may have therapeutical effect on atherosclerosis.更多还原